DATE: 7/17/2020

Case #: WA 323807

Via Electronic Mail

Robbie Lee Surratt, Jr.
Director of Pharmacy Operations
Solaris Pharmacy Inc. dba Solaris Pharmacy
2250 South FM 51
Suite 400
Decatur, TX 76234

Dear Mr. Surratt:

We are enclosing a copy of the Establishment Inspection Report (EIR) for the inspection conducted at your facility, Solaris Pharmacy, Inc. dba Solaris Pharmacy, located at 1308 East Old Chico Road, Decatur, Texas, from February 19, 2020, to February 26, 2020, by the U.S. Food and Drug Administration (FDA). In addition, we are enclosing the letter sent to the Texas State Board of Pharmacy for follow up.

When the Agency considers an inspection to be “closed” under 21 C.F.R. 20.64(d)(3), it will release a copy of the EIR to the inspected establishment.

The Agency continually works to make its regulatory process and activities more transparent for regulated industry. Releasing this EIR to you is part of this effort. The copy being provided to you comprises the narrative portion of the report; it may reflect redactions made by the Agency in accordance with the Freedom of Information Act (FOIA) and 21 C.F.R. Part 20. This, however, does not preclude you from requesting and possibly obtaining any additional information under FOIA.

If there is any question about the released information, please Dayna Martinez, Compliance Officer at (787) 729-8608, or by email at Dayna.Martinez@fda.hhs.gov.

U.S. Food & Drug Administration
Office of Pharmaceutical Quality Operations, Division II
4040 N. Central Expressway, Suite 300
Dallas, Texas 75204
www.fda.gov
Sincerely,

Dayna I.
Martinez -S
On behalf of
John W. Diehl, M.S
Director, Compliance Branch
Office of Pharmaceutical Quality Operations,
Division II

Enclosure: EIR, SRL

Cc: Texas State Board of Pharmacy (cover letter only)
Allison Vordenbaumen Benz
Executive Director/Secretary
333 Guadalupe, Ste #3-500
Austin, TX 78701